MISSISSAUGA, ON, Oct. 15, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that it has appointed pharmaceutical industry expert Frances Cloud to its board of directors. Ms. Cloud's appointment will take effect on November 1, 2018.
"We are delighted to welcome Frances and believe that she will provide crucial experience to our board and Company," said Graeme Duncan, Chief Executive Officer of Concordia. "Her expertise as a thought leader in the complex and dynamic European pharmaceutical industry will be particularly useful in helping the Company achieve its two key strategic guiding principles, namely, acquiring targeted products and companies in our core and proximate markets, and expanding our product portfolio."
Ms. Cloud has more than 20 years of experience in the pharmaceutical sector, including her time working as an analyst and investment banker for a number of banks, including Nomura International, IMI Securities and Swiss Bank Corporation (now part of UBS).
Ms. Cloud established Pharmacloud Research in 2009 to focus on covering the generic medicine industry in Europe, Indiaand the MENA region. Pharmacloud provides specialist advice and consultancy to the pharmaceutical industry and financial investors, including commercial due diligence on off-patent products.
Going forward, Concordia intends to build upon its current capabilities and global footprint across more than 90 countries, with a particular focus on both organic and inorganic growth in Europe.
About Concordia
Concordia is an international specialty pharmaceutical company with a diversified portfolio of more than 200 patented and off-patent products, and sales in more than 90 countries. Going forward, the Company is focused on becoming a leader in European specialty, off-patent medicines.
Concordia operates out of facilities in Mississauga, Ontario and, through its subsidiaries, operates out of facilities in Bridgetown, Barbados; London, England and Mumbai, India.